用蒙特卢卡斯特减少与万科米辛相关的急性损伤
Nicholas S Teran1,2, Cole S Hudson3, Kady Phe2
1Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy; Houston, Texas, 77204, United States of America.
The Journal of infectious diseases
|January 15, 2025
概括
蒙特卢卡斯特可能会防止万科米辛诱导的急性损伤 (AKI). 这项研究发现,在接受蒙特卢卡斯特与万科米辛一起治疗的患者中,AKI的患病率较低,这表明潜在的脏保护作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 抗菌疗法是一种抗菌疗法.
背景情况:
- 范科米辛对于治疗耐药格拉姆阳性感染至关重要,但与毒性有关.
- 临床前模型表明,蒙特卢卡斯特可以减少与万科米辛相关的急性损伤 (AKI).
研究的目的:
- 调查蒙特卢卡斯特是否能降低成年患者中与万科米辛相关的AKI的发生率.
主要方法:
- 成年患者接受静脉注射万科米辛的回顾性队列研究 (2020年1月至2024年1月).
- AKI是使用RIFLE标准确定的.
- 一个临床前模型探索了脏的保护机制.
主要成果:
- 与对照组 (n=330,10.6%,P=0.01) 相比,接受蒙特卢卡斯特的患者 (n=110) 的AKI率较低 (2.7%).
- 多变量分析表明蒙特卢卡斯特 (OR:0.26) 和男性性别对AKI有保护作用.
- 体重和ICU入院与AKI独立相关.
- 试验室研究表明,蒙特卢卡斯特激活了p62/KEAP-1/HO-1抗氧化途径,保护近端管细胞.
结论:
- 蒙特卢卡斯特可能会提供保护,防止与香草素相关的AKI.
- 这一发现可以减少患者的伤害和医疗保健成本.
- 需要进行前性研究来证实这些结果.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
241
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
241
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Renal Failure: Dose Adjustments
62
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
62
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236


